Last €24.39 EUR
Change Today +0.247 / 1.02%
Volume 50.0
8AK On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:37 AM 05/17/13 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Shane Cooke

President, Alkermes plc
AgeTotal Calculated CompensationThis person is connected to 6 board members in 2 different organizations across 4 different industries.

See Board Relationships
50$4,465,707
As of Fiscal Year 2012

Background*

Mr. Shane Cooke has been the President of Alkermes Plc since September 16, 2011. Mr. Cooke served as an Executive Vice President of Elan Drug Technologies Inc., since May 2007 and served as its Head of Elan Drug Technologies (EDT). He served as an Executive Vice President and Head of Elan Drug Technologies (EDT) at Elan Corporation, plc from July 2001 to September 15, 2011 and from May 2007 to September 15, 2011. He served as the Chief Financial Officer of Elan Corporation, ...

Read Full Background

Corporate Headquarters*

Connaught House
Dublin, Co. Dublin 4

Ireland

Phone: 353 1 772 8000
Fax: --

Board Members Memberships*

Director
2005-2011
Former Executive Vice President, Head of Elan Drug Technologies and Executive Director
2012-Present
Director, Member of Audit Committee, Member of Nominating & Corporate Governance Committee and Member of Compensation Committee

Education*

Unknown/Other Education
University College Dublin

Other Affiliations*

Annual Compensation*

Salary$319,085
Total Annual Compensation$319,085

Stock Options*

Restricted Stock Awards$730,000
All Other Compensation$504,000
Unexercisable Options350,000
Unexercisable Options Value$1,382,500
Total Value of Options$1,382,500
Total Number of Options350,000

Total Compensation*

Total Annual Cash Compensation$1,201,707
Total Short Term Compensation$319,085
Other Long Term Compensation$1,234,000
Total Calculated Compensation$4,465,707
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8AK:GR €24.39 EUR +0.247

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$807.7K
N. Anthony Coles M.D., M.P.H.Chairman, Chief Executive Officer and President
Onyx Pharmaceuticals, Inc.
$740.0K
John H. Johnson Executive Chairman, Chief Executive Officer and President
Dendreon Corp.
$736.4K
Rajesh C. Shrotriya M.D.Chairman, Chief Executive Officer, President, Chairman of Placement Committee and Chairman of Product Acquisition Committee
Spectrum Pharmaceuticals, Inc.
$2.4M
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
$722.2K
Compensation as of Fiscal Year 2012.

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.